In general, all of the current cancer vaccine platforms have advantages, such as inducing both humoral and adaptive immune systems, long-term stability, flexibility, high immunogenicity, clinical safety, and etc. [106,187,324,364,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424] along with disadvantages, such as antigen loss, low MHC expression, in appropriate APC uptake and antigen presentation, and etc. [106,201,287,363,383,411,412,416,418,419,422,423] that are summarized in details in Table 1. This evidence concerns the gene HLA-C and cancer.